The Experts below are selected from a list of 963 Experts worldwide ranked by ideXlab platform
Codrin Iacob - One of the best experts on this subject based on the ideXlab platform.
-
whole body positron emission tomography computed tomography imaging and staging of Orbital Lymphoma
Ophthalmology, 2006Co-Authors: Paul T Finger, M Kurli, Lawrence B Tena, Codrin IacobAbstract:Objectives To report the use of whole-body positron emission tomography fused with computed tomography (PET/CT) for the diagnosis and staging of Orbital Lymphoma. Design Retrospective observational case series. Participants Four patients with biopsy-proven Orbital Lymphoma were evaluated by 18-fluoro-2-deoxyglucose whole-body PET/CT imaging. Methods Positron emission tomography/CT images were studied for the presence of glucose uptake. Foci were considered suspicious based on their standardized uptake values (SUVs). Physiologic images (PET) and their anatomic counterparts (CT) were fused to allow form and function to be evaluated on the same diagnostic page. Main Outcome Measures Positron emission tomography/CT images were assessed for foci with abnormally high SUVs that correlated with biopsy-proven Lymphoma. Results Positron emission tomography/CT detected Orbital Lymphoma in 3 patients (75%). It also revealed systemic Lymphoma in 2 of the 4 patients. The 2 patients found to have systemic Lymphoma were diagnosed to have extranodal marginal zone B-cell Orbital Lymphoma of the mucosa-associated lymphoid tissue (MALT) type. Similarly, the 2 with negative PET/CT results also had Orbital MALT-type Lymphoma. We found that PET/CT imaging helped guide further management in all 4 patients. Conclusions Positron emission tomography/CT should be considered as a new method of diagnosing, staging, and restaging patients with Orbital Lymphomas.
-
Whole-Body Positron Emission Tomography/Computed Tomography Imaging and Staging of Orbital Lymphoma
Ophthalmology, 2006Co-Authors: Paul T Finger, M Kurli, Lawrence B Tena, Codrin IacobAbstract:Objectives To report the use of whole-body positron emission tomography fused with computed tomography (PET/CT) for the diagnosis and staging of Orbital Lymphoma. Design Retrospective observational case series. Participants Four patients with biopsy-proven Orbital Lymphoma were evaluated by 18-fluoro-2-deoxyglucose whole-body PET/CT imaging. Methods Positron emission tomography/CT images were studied for the presence of glucose uptake. Foci were considered suspicious based on their standardized uptake values (SUVs). Physiologic images (PET) and their anatomic counterparts (CT) were fused to allow form and function to be evaluated on the same diagnostic page. Main Outcome Measures Positron emission tomography/CT images were assessed for foci with abnormally high SUVs that correlated with biopsy-proven Lymphoma. Results Positron emission tomography/CT detected Orbital Lymphoma in 3 patients (75%). It also revealed systemic Lymphoma in 2 of the 4 patients. The 2 patients found to have systemic Lymphoma were diagnosed to have extranodal marginal zone B-cell Orbital Lymphoma of the mucosa-associated lymphoid tissue (MALT) type. Similarly, the 2 with negative PET/CT results also had Orbital MALT-type Lymphoma. We found that PET/CT imaging helped guide further management in all 4 patients. Conclusions Positron emission tomography/CT should be considered as a new method of diagnosing, staging, and restaging patients with Orbital Lymphomas.
Paul T Finger - One of the best experts on this subject based on the ideXlab platform.
-
Orbital Lymphoma an international multicenter retrospective study
American Journal of Ophthalmology, 2019Co-Authors: Tine Gadegaard Olsen, Bita Esmaeli, Frederik Holm, Lauge Hjorth Mikkelsen, Peter Kristian Rasmussen, Sarah E Coupland, Paul T Finger, Gerardo F Graue, Hans E Grossniklaus, Santosh G HonavarAbstract:Purpose To investigate and characterize the clinical features of subtype-specific Orbital Lymphoma. Design Retrospective, interventional case series. Methods The study included 7 international eye cancer centers. Patient data were collected from January 1, 1980 through December 31, 2017. A total of 797 patients with a histologically verified Orbital Lymphoma were included. The primary endpoints were overall survival, disease-specific survival, and progression-free survival. Results The median age was 64 years, and 51% of patients (n = 407) were male. The majority of Lymphomas were of B-cell origin (98%, n = 779). Extranodal marginal zone B-cell Lymphoma (EMZL) was the most frequent subtype (57%, n = 452), followed by diffuse large B-cell Lymphoma (DLBCL) (15%, n = 118), follicular Lymphoma (FL) (11%, n = 91), and mantle cell Lymphoma (MCL) (8%, n = 66). Localized Ann Arbor stage IE EMZL and FL were frequently treated with external beam radiation therapy. DLBCL, MCL, and disseminated EMZL and FL were primarily treated with chemotherapy. EMZL and FL patients had a markedly better prognosis (10-year disease-specific survival of 92% and 71%, respectively) than DLBCL and MCL patients (10-year disease-specific survival of 41% and 32%, respectively). Conclusions Four Lymphoma subtypes were primarily found in patients with Orbital Lymphoma: EMZL, DLBCL, FL, and MCL. The histologic subtype was found to be the main predictor for outcome, with EMZL and FL patients having a markedly better prognosis than DLBCL and MCL.
-
Orbital Lymphoma—An International Multicenter Retrospective Study
American Journal of Ophthalmology, 2018Co-Authors: Tine Gadegaard Olsen, Bita Esmaeli, Frederik Holm, Lauge Hjorth Mikkelsen, Peter Kristian Rasmussen, Sarah E Coupland, Paul T Finger, Gerardo F Graue, Hans E Grossniklaus, Santosh G HonavarAbstract:Purpose To investigate and characterize the clinical features of subtype-specific Orbital Lymphoma. Design Retrospective, interventional case series. Methods The study included 7 international eye cancer centers. Patient data were collected from January 1, 1980 through December 31, 2017. A total of 797 patients with a histologically verified Orbital Lymphoma were included. The primary endpoints were overall survival, disease-specific survival, and progression-free survival. Results The median age was 64 years, and 51% of patients (n = 407) were male. The majority of Lymphomas were of B-cell origin (98%, n = 779). Extranodal marginal zone B-cell Lymphoma (EMZL) was the most frequent subtype (57%, n = 452), followed by diffuse large B-cell Lymphoma (DLBCL) (15%, n = 118), follicular Lymphoma (FL) (11%, n = 91), and mantle cell Lymphoma (MCL) (8%, n = 66). Localized Ann Arbor stage IE EMZL and FL were frequently treated with external beam radiation therapy. DLBCL, MCL, and disseminated EMZL and FL were primarily treated with chemotherapy. EMZL and FL patients had a markedly better prognosis (10-year disease-specific survival of 92% and 71%, respectively) than DLBCL and MCL patients (10-year disease-specific survival of 41% and 32%, respectively). Conclusions Four Lymphoma subtypes were primarily found in patients with Orbital Lymphoma: EMZL, DLBCL, FL, and MCL. The histologic subtype was found to be the main predictor for outcome, with EMZL and FL patients having a markedly better prognosis than DLBCL and MCL.
-
whole body positron emission tomography computed tomography imaging and staging of Orbital Lymphoma
Ophthalmology, 2006Co-Authors: Paul T Finger, M Kurli, Lawrence B Tena, Codrin IacobAbstract:Objectives To report the use of whole-body positron emission tomography fused with computed tomography (PET/CT) for the diagnosis and staging of Orbital Lymphoma. Design Retrospective observational case series. Participants Four patients with biopsy-proven Orbital Lymphoma were evaluated by 18-fluoro-2-deoxyglucose whole-body PET/CT imaging. Methods Positron emission tomography/CT images were studied for the presence of glucose uptake. Foci were considered suspicious based on their standardized uptake values (SUVs). Physiologic images (PET) and their anatomic counterparts (CT) were fused to allow form and function to be evaluated on the same diagnostic page. Main Outcome Measures Positron emission tomography/CT images were assessed for foci with abnormally high SUVs that correlated with biopsy-proven Lymphoma. Results Positron emission tomography/CT detected Orbital Lymphoma in 3 patients (75%). It also revealed systemic Lymphoma in 2 of the 4 patients. The 2 patients found to have systemic Lymphoma were diagnosed to have extranodal marginal zone B-cell Orbital Lymphoma of the mucosa-associated lymphoid tissue (MALT) type. Similarly, the 2 with negative PET/CT results also had Orbital MALT-type Lymphoma. We found that PET/CT imaging helped guide further management in all 4 patients. Conclusions Positron emission tomography/CT should be considered as a new method of diagnosing, staging, and restaging patients with Orbital Lymphomas.
-
Whole-Body Positron Emission Tomography/Computed Tomography Imaging and Staging of Orbital Lymphoma
Ophthalmology, 2006Co-Authors: Paul T Finger, M Kurli, Lawrence B Tena, Codrin IacobAbstract:Objectives To report the use of whole-body positron emission tomography fused with computed tomography (PET/CT) for the diagnosis and staging of Orbital Lymphoma. Design Retrospective observational case series. Participants Four patients with biopsy-proven Orbital Lymphoma were evaluated by 18-fluoro-2-deoxyglucose whole-body PET/CT imaging. Methods Positron emission tomography/CT images were studied for the presence of glucose uptake. Foci were considered suspicious based on their standardized uptake values (SUVs). Physiologic images (PET) and their anatomic counterparts (CT) were fused to allow form and function to be evaluated on the same diagnostic page. Main Outcome Measures Positron emission tomography/CT images were assessed for foci with abnormally high SUVs that correlated with biopsy-proven Lymphoma. Results Positron emission tomography/CT detected Orbital Lymphoma in 3 patients (75%). It also revealed systemic Lymphoma in 2 of the 4 patients. The 2 patients found to have systemic Lymphoma were diagnosed to have extranodal marginal zone B-cell Orbital Lymphoma of the mucosa-associated lymphoid tissue (MALT) type. Similarly, the 2 with negative PET/CT results also had Orbital MALT-type Lymphoma. We found that PET/CT imaging helped guide further management in all 4 patients. Conclusions Positron emission tomography/CT should be considered as a new method of diagnosing, staging, and restaging patients with Orbital Lymphomas.
Brian T Chankai - One of the best experts on this subject based on the ideXlab platform.
-
combined positron emission tomography computed tomography imaging of Orbital Lymphoma
American Journal of Ophthalmology, 2005Co-Authors: Brian T ChankaiAbstract:Purpose To report a case of Orbital Lymphoma with systemic dissemination that was identified and localized by combined positron emission tomography (PET)/computed tomography. Design Case report. Methods A 75-year-old woman presented with a 6-month history of painless, progressive fullness of her right upper eyelid. A PET/computed tomography was obtained to provide functional and anatomic assessment of the orbits. An orbitotomy was performed with sub-total excision of the lesion to obtain histologic diagnosis. Results The PET/computed tomography scan revealed intensive uptake of tracer in a right Orbital mass measuring 2.3 × 1.8 × 2.6 cm. Foci of abnormal tracer uptake were also noted in the right neck, right hilar region, and central abdomen. Histopathologic findings were consistent with follicular cell Lymphoma. Conclusions The combination of PET/computed tomography provides accurate and precise information in an expedited manner not offered by alternative imaging modalities. PET/computed tomography imaging should be considered in the evaluation of Orbital neoplasms, especially if Lymphoma is suspected.
Amadeo Muntane - One of the best experts on this subject based on the ideXlab platform.
-
Orbital Lymphoma: imaging features and differential diagnosis
Insights into Imaging, 2012Co-Authors: Gema Priego, Carles Majos, Fina Climent, Amadeo MuntaneAbstract:Purpose Patterns of Orbital Lymphoma at diagnosis and follow-up are described. We also discuss differential diagnosis of Orbital masses. Materials and methods This pictorial review contains 19 cases of Orbital Lymphoma before and after treatment. Superior-lateral quadrant and extra-conal location were observed predominantly. Effective response after treatment was presented on follow-up imaging, although few local relapses were found. Further follow-up showed no changes of residual images. Discussion Location of Orbital masses can help in the differential diagnosis. Moreover, imaging features of Lymphoma at diagnosis can be useful in planning surgical biopsy. Pattern of follow-up described may be relevant on monitoring imaging. Teaching points • Orbital Lymphoma involves mainly superior-lateral quadrant and the Orbital structures inside . • Location of retrobulbar mass-like lesions are useful information in the differential diagnosis . • Satisfactory response is detected after treatment, however relapse is noted, so follow-up is needed .
-
Orbital Lymphoma imaging features and differential diagnosis
Insights Into Imaging, 2012Co-Authors: Gema Priego, Carles Majos, Fina Climent, Amadeo MuntaneAbstract:Purpose Patterns of Orbital Lymphoma at diagnosis and follow-up are described. We also discuss differential diagnosis of Orbital masses.
M Kurli - One of the best experts on this subject based on the ideXlab platform.
-
whole body positron emission tomography computed tomography imaging and staging of Orbital Lymphoma
Ophthalmology, 2006Co-Authors: Paul T Finger, M Kurli, Lawrence B Tena, Codrin IacobAbstract:Objectives To report the use of whole-body positron emission tomography fused with computed tomography (PET/CT) for the diagnosis and staging of Orbital Lymphoma. Design Retrospective observational case series. Participants Four patients with biopsy-proven Orbital Lymphoma were evaluated by 18-fluoro-2-deoxyglucose whole-body PET/CT imaging. Methods Positron emission tomography/CT images were studied for the presence of glucose uptake. Foci were considered suspicious based on their standardized uptake values (SUVs). Physiologic images (PET) and their anatomic counterparts (CT) were fused to allow form and function to be evaluated on the same diagnostic page. Main Outcome Measures Positron emission tomography/CT images were assessed for foci with abnormally high SUVs that correlated with biopsy-proven Lymphoma. Results Positron emission tomography/CT detected Orbital Lymphoma in 3 patients (75%). It also revealed systemic Lymphoma in 2 of the 4 patients. The 2 patients found to have systemic Lymphoma were diagnosed to have extranodal marginal zone B-cell Orbital Lymphoma of the mucosa-associated lymphoid tissue (MALT) type. Similarly, the 2 with negative PET/CT results also had Orbital MALT-type Lymphoma. We found that PET/CT imaging helped guide further management in all 4 patients. Conclusions Positron emission tomography/CT should be considered as a new method of diagnosing, staging, and restaging patients with Orbital Lymphomas.
-
Whole-Body Positron Emission Tomography/Computed Tomography Imaging and Staging of Orbital Lymphoma
Ophthalmology, 2006Co-Authors: Paul T Finger, M Kurli, Lawrence B Tena, Codrin IacobAbstract:Objectives To report the use of whole-body positron emission tomography fused with computed tomography (PET/CT) for the diagnosis and staging of Orbital Lymphoma. Design Retrospective observational case series. Participants Four patients with biopsy-proven Orbital Lymphoma were evaluated by 18-fluoro-2-deoxyglucose whole-body PET/CT imaging. Methods Positron emission tomography/CT images were studied for the presence of glucose uptake. Foci were considered suspicious based on their standardized uptake values (SUVs). Physiologic images (PET) and their anatomic counterparts (CT) were fused to allow form and function to be evaluated on the same diagnostic page. Main Outcome Measures Positron emission tomography/CT images were assessed for foci with abnormally high SUVs that correlated with biopsy-proven Lymphoma. Results Positron emission tomography/CT detected Orbital Lymphoma in 3 patients (75%). It also revealed systemic Lymphoma in 2 of the 4 patients. The 2 patients found to have systemic Lymphoma were diagnosed to have extranodal marginal zone B-cell Orbital Lymphoma of the mucosa-associated lymphoid tissue (MALT) type. Similarly, the 2 with negative PET/CT results also had Orbital MALT-type Lymphoma. We found that PET/CT imaging helped guide further management in all 4 patients. Conclusions Positron emission tomography/CT should be considered as a new method of diagnosing, staging, and restaging patients with Orbital Lymphomas.
